Minimally invasive tubular access for posterior cervical foraminotomy

Branch, Byron C.; Hilton, Donald L.; Watts, Clark

doi:10.4103/2152-7806.157308

Cited by 29 publications

(9 citation statements)

References 14 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other studies from the Asian population have shown similar results demonstrating that the presence of BIM deletion polymorphism is a negative predictive factor of response rate, PFS and OS to EGFR TKIs [24, 25, 27]. In a meta-analysis of six original eligible studies including 871 NSCLC patients [29], patients BIM del+ had poor response to EGFR TKI therapy (p= 0.001, OR = 0.39; 95% CI = 0.23–0.67). Disease control rate (DCR) with EGFR TKI treatment was significantly decreased in BIM del+ patients (p= 0.007, OR = 0.46, 95% CI = 0.25–0.85).…”

Section: Discussionmentioning

confidence: 83%

BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations

et al. 2016

View full text Add to dashboard Cite

Background: Germline alterations in the proapoptotic protein Bcl-2-like 11 (BIM) can have a crucial role in diverse tumors. To determine the clinical utility of detecting BIM deletion polymorphisms (par4226 bp/ par363 bp) in EGFR positive non-smallcell lung cancer (NSCLC) we examined the outcomes of patients with and without BIM alterations.Results: BIM deletion was present in 14 patients (15.7%). There were no significant differences between patients with and without BIM-del in clinical characteristics or EGFR mutation type; however, those with BIM-del had a worse overall response rate (ORR) to erlotinib (42.9% vs. 73.3% in patients without BIMdel; p=0.024) as well as a significantly shorter progression-free survival (PFS) (10.8 BIM-del+ vs. 21.7 months for patients without BIM-del; p=0.029) and overall survival (OS) (15.5 BIM-del+ vs. 34.0 months for patients without BIM-del; p=0.035). Multivariate Cox regression analysis showed that BIM-del+ was an independent indicator of shorter PFS (HR 3.0; 95%CI 1.2-7.6; p=0.01) and OS (HR 3.4; 95%CI 1.4-8.3; p=0.006).Methods: We studied 89 NSCLC Hispanic patients with EGFR mutation who were treated with erlotinib between January 2009 and November 2014. BIM deletion polymorphisms (BIM-del) was analyzed by PCR in formalin-fixed paraffin-embedded

show abstract

Section: Discussionmentioning

confidence: 83%

BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In breast cancer, overexpression of HER2 is found in approximately 10%–30% of patients and is associated with reduced survival [ 30 ]. In addition, EGFR deletion can also be detected in malignant gliomas, NSCLC, breast cancer, medulloblastoma and ovarian cancer [ 31 , 32 ]. The most common EGFR deletion mutant is EGFR VIII.…”

Section: Ptk and Tumormentioning

confidence: 99%

Advances in studies of tyrosine kinase inhibitors and their acquired resistance

et al. 2018

View full text Add to dashboard Cite

Protein tyrosine kinase (PTK) is one of the major signaling enzymes in the process of cell signal transduction, which catalyzes the transfer of ATP-γ-phosphate to the tyrosine residues of the substrate protein, making it phosphorylation, regulating cell growth, differentiation, death and a series of physiological and biochemical processes. Abnormal expression of PTK usually leads to cell proliferation disorders, and is closely related to tumor invasion, metastasis and tumor angiogenesis. At present, a variety of PTKs have been used as targets in the screening of anti-tumor drugs. Tyrosine kinase inhibitors (TKIs) compete with ATP for the ATP binding site of PTK and reduce tyrosine kinase phosphorylation, thereby inhibiting cancer cell proliferation. TKI has made great progress in the treatment of cancer, but the attendant acquired acquired resistance is still inevitable, restricting the treatment of cancer. In this paper, we summarize the role of PTK in cancer, TKI treatment of tumor pathways and TKI acquired resistance mechanisms, which provide some reference for further research on TKI treatment of tumors.

show abstract

“…As a result, our meta-analysis of these studies also reflected this finding. Although several previous meta-analyses9,33–36 mentioned similar findings regarding PFS, the current pooled analysis containing more eligible studies further provided a possibility to analyze other clinical outcome measures. As a comprehensive meta-analysis of PFS, OS, ORR and DCR with the largest sample size to date, our study provided a more reliable answer regarding the impact of BIM polymorphism status on treatment efficacy of EGFR-TKIs in advanced and metastatic NSCLC patients with EGFR mutations.…”

Section: Discussionmentioning

confidence: 64%

Exploratory cohort study and meta-analysis of <em>BIM</em> deletion polymorphism in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors

Sun¹,

Yu²,

Wang³

et al. 2017

OTT

View full text Add to dashboard Cite

BackgroundNon-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations might develop primary and secondary resistance to tyrosine kinase inhibitors (TKIs). The proapoptotic protein Bcl-2-like 11 (BIM) is a key modulator of apoptosis triggered by EGFR-TKIs. The recent studies have indicated that some patients with positive EGFR mutations were refractory to EGFR-TKIs if they harbored a BIM deletion polymorphism. The purpose of this study was to investigate whether BIM polymorphism predicts treatment efficacy of EGFR-TKIs in Chinese NSCLC patients.Patients and methodsA cohort of advanced NSCLC patients with EGFR mutations and treated with EGFR-TKIs (gefitinib or erlotinib) were recruited. We drew peripheral blood to determinate BIM deletion status and then compared patients’ clinical outcomes according to the BIM deletion status. Additionally, we electronically searched eligible cohort studies and conducted a meta-analysis to pool event risk.ResultsThe exploratory cohort study included 140 patients. Patients with and without the BIM deletion polymorphism had similar objective response rates (ORRs, 48.5 vs 63.0%, P=0.16), disease control rate (DCR, 93.9 vs 97.0%, P=0.60) and adverse reactions. Similar progression-free survival (PFS) and overall survival (OS) were noted in overall population (P=0.27 for PFS and P=0.61 for OS) and prespecified patient subgroups. The meta-analysis included 10 eligible cohort studies involving 1,317 NSCLC patients. It showed the positive BIM deletion was associated with shorter PFS (hazard ratio =1.45; P=0.02). Nonsignificant differences existed for ORR, DCR and OS.ConclusionThe expanded meta-analysis results demonstrated the positive BIM deletion predicts shorter PFS in NSCLC patients after treatment with EGFR-TKIs while other clinical measures do not. A large multicenter well-designed cohort study involving other concurrent genetic alterations is warranted.

show abstract

Minimally invasive tubular access for posterior cervical foraminotomy

Cited by 29 publications

References 14 publications

BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations

BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations

Advances in studies of tyrosine kinase inhibitors and their acquired resistance

Exploratory cohort study and meta-analysis of <em>BIM</em> deletion polymorphism in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors

Contact Info

Product

Resources

About